Gross Profit Margin (Quarterly) Chart

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 75.30%
March 31, 2026 80.92%
December 31, 2025 87.65%
September 30, 2025 86.56%
June 30, 2025 86.96%
March 31, 2025 83.49%
December 31, 2024 85.20%
September 30, 2024 82.94%
June 30, 2024 84.24%
March 31, 2024 82.56%
December 31, 2023 79.04%
September 30, 2023 80.86%
June 30, 2023 87.88%
March 31, 2023 75.92%
December 31, 2022 79.28%
September 30, 2022 75.08%
June 30, 2022 74.54%
March 31, 2022 75.97%
December 31, 2021 79.57%
September 30, 2021 78.90%
June 30, 2021 78.42%
March 31, 2021 78.59%
December 31, 2020 79.84%
September 30, 2020 78.44%
June 30, 2020 76.31%
Date Value
March 31, 2020 75.37%
December 31, 2019 85.35%
September 30, 2019 78.02%
June 30, 2019 78.71%
March 31, 2019 73.73%
December 31, 2018 78.26%
September 30, 2018 76.34%
June 30, 2018 79.46%
March 31, 2018 73.24%
December 31, 2017 79.32%
September 30, 2017 74.98%
June 30, 2017 73.57%
March 31, 2017 69.70%
December 31, 2016 75.37%
September 30, 2016 70.66%
June 30, 2016 73.89%
March 31, 2016 71.57%
December 31, 2015 68.92%
September 30, 2015 67.56%
June 30, 2015 69.70%
March 31, 2015 64.77%
December 31, 2014 63.68%
September 30, 2014 59.57%
June 30, 2014 60.65%
March 31, 2014 60.51%

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
Amarin Corp. Plc 34.00%
Prothena Corp. Plc 9.50%
Biogen, Inc. 61.37%
Exelixis, Inc. 96.71%
Incyte Corp. 92.57%